Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Learn more about:
Related Clinical Trial
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer Retrospective Study of Brachytherapy Groningen International Study on Sentinel Nodes in Vulvar Cancer-III Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study Education, Immigration and HPV Vaccination: an Informational Randomized Trial Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years Serial MRI Scans During Radiation Therapy A Safety and Efficacy Study of Intra-tumoural Diffusing Alpha Radiation Emitters for the Treatment of Vulva Cancer Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Cisplatin+Pembrolizumab+RT in Vulvar Cancer Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery MR-HIFU for Recurrent Gynaecological Cancer Pelvic Floor Disorders in Survivors of Gynecologic Malignancies Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Validation of a Nutrition Screening Tool A Survivorship Care Plan for Gynaecological Cancer Patients Self-Advocacy Serious Game in Advanced Cancer Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) Chemoradiation-Induced Nausea and Emesis: Quality of Life A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies ChemoFx® PRO – A Post-Market Data Collection Study Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Image-Guided Gynecologic Brachytherapy Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Topical Imiquimod in Treating Patients With Recurrent Paget’s Disease of the Vulva Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox. The Impact of the “WOMAN-PRO II Program” on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence CaptHPV : Validation of the Method “CaptHPV” for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Effectiveness of an Individualized Symptom Education Program (ISEP) A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Study to Evaluate the Role of PlasmaJet in Patients Undergoing Groin Node Dissection for Vulval Cancer Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer OCT-AF Imaging of Pre-cancers of Vulva and Cervix Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients. Quality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer Sentinel Node Extended in Squamous Cell Vulvar Cancer Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva

Brief Title

Pelvic Floor Disorders in Survivors of Gynecologic Malignancies

Official Title

The Prevalence and Predictive Factors of Pelvic Floor Disorders in Gynecologic Malignancy Survivors

Brief Summary

      Pelvic Floor dysfunction affects the quality of life of women. However, the prevalence and
      risk factors for pelvic floor disorders (PFD) in survivors of gynecologic malignancies are
      not known. The investigators plan to perform an observational study including survivors of
      gynecologic malignancies. Questionnaires for diagnosis of pelvic floor disorders will be
      mailed to survivors to generate prevalence rates and risk factors for PFD in women with a
      history of a gynecologic cancer diagnosis.

Detailed Description

      Pelvic floor disorders negatively impact the quality of life of those afflicted by pelvic
      organ prolapse, lower urinary tract symptoms, defecatory or sexual dysfunction, or pain.
      Women who present for routine gynecologic care often have undiagnosed pelvic floor disorders,
      and physicians may not specifically question women to elicit pelvic floor symptoms. In the
      United States 24% of women report at least one pelvic floor disorder, which increases with
      age, parity , obesity. Gynecologic cancer survivors are a unique population who undergo a
      variety treatment regimens including surgery, chemotherapy, and radiation. Radical
      hysterectomy, a common surgical treatment for gynecologic cancers, is a well-established
      cause for lower urinary tract dysfunction. In contrast, data are lacking regarding risk
      factors for pelvic organ prolapse or fecal incontinence. Survivors of gynecologic
      malignancies may be at increased risk for symptomatic pelvic floor disorders, but may not be
      diagnosed due to lack of inquiry of these symptoms by practitioners. In addition, a recent
      qualitative study found that survivors of gynecologic malignancies believed that pelvic floor
      symptoms were an inevitable, untreatable corollary to treatment for their cancer and thus did
      not seek treatment. Furthermore, the study participants reported that they felt healthy
      despite these symptoms because of their oncologists assessment of their remission status. The
      lack of diagnosis and treatment of pelvic floor disorders has clinical and quality of life
      implications for the growing numbers of gynecologic malignancy survivors. The objective of
      this study is to identify the prevalence of an risk factors for pelvic floor disorders in
      women after treatment for gynecologic cancer. Our rationale for this project is that the
      investigators believe that pelvic floor disorders affect the quality of life of gynecologic
      cancer survivors and should be quantified. Successful completion of this study will provide
      evidence for practitioners to screen and treat pelvic floor disorders in gynecologic
      malignancy survivors.

Study Type


Primary Outcome

Urinary incontinence


Uterine Cancer



Study Arms / Comparison Groups

 Subjects exposed to radiation


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 2011

Completion Date

September 2017

Primary Completion Date

October 2012

Eligibility Criteria

        Inclusion Criteria:

          -  Women with documented surgery for gynecologic malignancies at any of the three UPHS
             associated hospitals in center city Philadelphia (e.g., HUP, Pennsylvania hospital)
             and an accessible electronic medical record from the time of cancer diagnosis and

          -  Gynecologic cancer survivors at least 20 years of age diagnosed and treated for
             uterine, ovarian, peritoneal, fallopian tube, cervical, or vulvar tumors between 2008
             to July 2010 will be included

        Exclusion Criteria:

          -  Women who are pregnant, with benign tumors, those lost to follow-up, or deceased will
             be excluded from this study.

          -  Patients unable to complete a written survey due to physical or mental disabilities
             will also be excluded.




20 Years - N/A

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID

UPCC 35810

Responsible Party


Study Sponsor

Abramson Cancer Center of the University of Pennsylvania

Study Sponsor

, , 

Verification Date

April 2020